Search Results
Your search for The matches 36113 pages
Showing 23101 - 23150Phase II Trial Evaluates New Gene Therapy for Non–Muscle Invasive Bladder Cancer After BCG
A novel approach using intravesical gene therapy showed promising activity in a phase II trial that enrolled patients with bacillus Calmette-Guérin (BCG)-refractory or -relapsed nonmuscle invasive bladder cancer.1 The rate of high-grade relapse-free survival at 12 months was 35% in patients treated ...
Make Vaccination Great Again
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. It affects 80% of individuals, with the initial infection usually occurring between the ages of 15 and 24. Persistent infection with oncogenic HPV genotypes, primarily 16 and 18, is the cause of virtually all...
How Stupid Cancer Is Building a Support Community for AYA Survivors
In 1995, Matthew Zachary, an aspiring concert pianist and composer, was en route to graduate school to study film composition when he lost all fine-motor coordination in his left hand, was diagnosed with pediatric brain cancer (medulloblastoma), told he would never play again, and was given 6...
FALCON Trial Informs the Evolving Role of Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Endocrine therapy for breast cancer has evolved over the years. Initial endocrine therapies consisted of ablative procedures (oophorectomy, adrenalectomy, and hypophysectomy). With the availability of pharmaceutical estrogens, progestins, and androgens, ablative procedure utilization begin to...
ASCO Quality Care 2017: Reducing Overuse of Colony-Stimulating Factors in Febrile Neutropenia Without Compromising Patient Safety
In a retrospective cohort study, Adeboyeje et al found that a utilization management tool that makes real-time care recommendations can help reduce overuse of substances that assist the bone marrow in producing blood cells, called colony-stimulating factors, in attempts to prevent fevers in...
ASCO Quality Care 2017: Cost and Survival Analysis Before and After Implementation of Clinical Pathways for Patients With Stage IV NSCLC
In a study reported at the 2017 Quality Care Symposium by Zheng et al (Abstract 3) and published in the Journal of Oncology Practice by Jackman et al, researchers explored the use of clinical pathways to support clinical decision-making and manage resources for patients with late-stage...
Financial Stress in Patients With Locally Advanced Head and Neck Cancer
In a single-institution study reported in the Journal of Oncology Practice, de Souza et al found that two-thirds of patients with locally advanced head and neck cancer had to use a financial coping strategy to help pay for care within the first 6 months of treatment. Study Details The study...
ASCO Quality Care 2017: Reduction in Chemotherapy Errors Through Improvement Science
The majority of children with cancer are treated with complicated chemotherapy regimens that include multiple drugs, demanding monitoring schedules and complex dosing based on body surface area that often require changes in dose. Given this high risk for error in treating children with these highly ...
Can Histone Deacetylase Inhibitors Reverse Resistance to Angiogenesis Inhibitors?
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al found evidence that the histone deacetylase (HDAC) inhibitor abexinostat may act to reverse resistance to the vascular endothelial growth factor (VEGF) inhibitor pazopanib (Votrient) via epigenetic modulation of VEGF in ...
Nivolumab in Previously Treated Unresectable Metastatic Squamous Cell Carcinoma of the Anal Canal
In a phase II trial reported in The Lancet Oncology, Morris et al found that nivolumab (Opdivo) was active in previously treated unresectable metastatic squamous cell carcinoma of the anal canal. This malignancy is associated with human papillomavirus (HPV) infection, with the rationale for...
Barriers to Clinical Trial Accrual Include Trial Sponsorship and Time to Enrolling First Patient, Study Finds
A study by researchers from The University of Texas MD Anderson Cancer Center investigating factors associated with slow participant accrual into phase I to III cancer clinical trials at their institution has found trials initiated through national cooperative groups and the time taken from trial...
Brian Weiss, MD, on Reducing Treatment Errors With Improvement Science
Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).
Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)
Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival...
Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices
Gabrielle Rocque, MD, of the University of Alabama at Birmingham, discusses the challenges of implementing Oncology Care Model requirements, such as providing treatment plans, and the opportunities to transform practices with improved workflow and patient outcomes.
Gwendolyn P. Quinn, PhD, on Underserved Cancer Patients and Survivors: Are We Listening to Them?
Gwendolyn P. Quinn, PhD, of Moffitt Cancer Center, discusses the challenges that minority, LGBTQ, low-literacy, and underserved populations face in getting their voices heard and what it will take to change that.
Julie Bryar Porter, MS, on Improving Care: One Center’s Experience
Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).
Blase N. Polite, MD, MPP: The Oncology Care Model in Academia
Blase N. Polite, MD, MPP, of the University of Chicago, discusses implementing the Oncology Care Model in an academic health center and the challenges of getting buy-in from faculty members.
Laura E. Panattoni, PhD, on Costs of Preventable Emergency Department Use
Laura E. Panattoni, PhD, of the Fred Hutchinson Cancer Research Center, discusses results from a regional study on emergency department costs during cancer treatment and the need to focus on managing symptoms (Abstract 2).
Nicole Mittmann, PhD, on Breast Cancer Well Follow-up
Nicole Mittmann, PhD, of the Sunnybrook Health Sciences Centre, discusses her study findings on transitioning breast cancer survivors to primary care and the savings in resources and dollars that accrued as a result (Abstract 1).
Robert S. Miller, MD, on CancerLinQ: Big Data and Clinical Effectiveness
Robert S. Miller, MD, of ASCO, updates the progress of CancerLinQ and its data set, now being used by oncologists to track quality measurement and reporting.
Greg D. Judy, MD, on Safety Incidents in Radiotherapy
Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.
Diana D. Jeffery, PhD, on Mental Health Comorbidities: Predictors of Cost and Utilization
Diana D. Jeffery, PhD, of the Defense Health Agency, discusses the need to screen for mental health comorbidities, including depression, anxiety, adjustment disorders, substance use disorders, and persistent mental illnesses, as shown in a study of breast and prostate cancer patients (Abstract 18).
Caleb Dulaney, MD, on Breast Cancer: Improving Online Patient Information
Caleb Dulaney, MD, of the University of Alabama at Birmingham, discusses ways to broaden and improve the quality of information that women with breast cancer find—in English and Spanish—on websites of nationally recognized cancer centers (Abstract 135).
John V. Cox, DO, MBA, on 2017 Quality Care Symposium Highlights: Expert Perspective
John V. Cox, DO, MBA, of the Parkland Health System/UTSW, discusses some of the key presentations at the 2017 Quality Care Symposium (Abstracts 3, 37, 52).
Ethan M. Basch, MD, on Symptom Control and Quality: The Patient’s Voice
Ethan M. Basch, MD, of The University of North Carolina at Chapel Hill, discusses programs—now rolling out at various institutions—that use direct patient reporting of symptoms as a part of quality assessment (Posters 61, 81; Abstract 218).
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
Exercise and/or psychological therapy may work better than medications to reduce cancer-related fatigue and should be recommended first to patients, according to a Wilmot Cancer Institute-led study published by Mustian et al in JAMA Oncology. “If a [patient with cancer] is having trouble...
Effect of Scalp Cooling on Hair Loss in Women Receiving Nonanthracycline Chemotherapy for Breast Cancer
In a prospective cohort study reported in JAMA, Rugo et al found that use of a scalp-cooling device reduced hair loss in women receiving nonanthracycline chemotherapy for early-stage breast cancer. Study Details In the study, 101 evaluable patients from 5 U.S. centers with stage I or II breast...
Hormone Maintenance Therapy in Low-Grade Serous Cancer of the Ovary or Peritoneum
In a single-institution experience reported in the Journal of Clinical Oncology, Gershenson et al at MD Anderson Cancer Center found that hormonal maintenance therapy was associated with improved progression-free survival among women with stage II to IV low-grade serous carcinoma of the ovary or...
Adding Rituximab to Standard Therapy in Interim PET–Positive Advanced Hodgkin Lymphoma
As reported in The Lancet Oncology by Borchmann et al, a phase III German Hodgkin Study Group trial in advanced Hodgkin lymphoma showed no progression-free survival benefit of adding rituximab (Rituxan) in patients with positive positron-emission tomography (PET) findings after two courses (PET-2)...
Phase III APHINITY Study: Adjuvant Pertuzumab/Trastuzumab/Chemotherapy Increased Invasive Disease–Free Survival in HER2-Positive Breast Cancer
Genentech, the Breast International Group, the Breast European Adjuvant Study Team, and the Frontier Science Foundation have announced positive results from the phase III APHINITY study. The study met its primary endpoint and showed that adjuvant treatment with the...
Single Dose of Brachytherapy May Be an Effective Treatment for Localized Prostate Cancer
Results from a new prospective clinical trial indicate that high–dose rate (HDR) brachytherapy administered in a single 19-Gy treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. The study was reported by Krauss et al in...
Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, a research team from The University of Texas MD Anderson Cancer Center reported in a study by Balasenthil et al in the ...
11-Year Follow-up of Adjuvant Trastuzumab in the HERA Trial
In the 11-year follow-up of the HERA trial reported in The Lancet, Cameron et al found that 1 year of trastuzumab (Herceptin) following adjuvant therapy for HER2-positive breast cancer remained associated with improved disease-free and overall survival compared with observation. No additional...
Feasibility of Patient Reporting of Adverse Events in Cancer Clinical Trials
In a study reported in JAMA Oncology, Basch et al found that use of patient-reported outcome questionnaires to report symptomatic adverse events was feasible in the setting of multicenter cancer treatment trials. Study Details In the study, 361 consecutive patients enrolled in 1 of 9 U.S....
Clofarabine-Based Consolidation in Younger Patients With Acute Myeloid Leukemia in First Remission
In a French phase II trial reported in the Journal of Clinical Oncology, Thomas et al found that clofarabine-based consolidation may provide improved relapse-free survival vs conventional high-dose cytarabine in postremission treatment in younger patients with acute myeloid leukemia (AML) and no...
Pembrolizumab vs Chemotherapy in Second-Line Treatment of Advanced Urothelial Carcinoma
In a phase III KEYNOTE-045 trial reported in The New England Journal of Medicine, Bellmunt et al found that pembrolizumab (Keytruda) significantly improved overall survival vs investigator choice of chemotherapy as second-line treatment in patients with advanced urothelial cancer whose disease...
Study Finds Sharp Rise in Colon and Rectal Cancers in Young Adults
Although the overall incidence rate of colorectal cancer in the United States has been declining rapidly since the mid-1980s, the decrease has been in older adults. During this same period, incidence rates have been increasing sharply for adults younger than age 50, finds a study by the American...
Holger N. Lode, MD: Neuroblastoma Survival Update (German Language Version) 
Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor genotypes and Fc-receptor polymorphisms. (Abstract 111)
FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhea
On February 28, the U.S. Food and Drug Administration (FDA) approved telotristat ethyl (Xermelo) tablets in combination with somatostatin analog therapy for the treatment of adults with carcinoid syndrome diarrhea that somatostatin analog therapy alone has inadequately controlled. About...
Patients With Cancer History More Likely to Change Prescriptions to Save Money
A new study led by American Cancer Society investigators found that cancer survivors are more likely to change their prescription drug use for financial reasons than those without a cancer history. These findings were published by Zheng et al in Cancer. The rising cost of cancer drugs imposes a...
Poor Diet During Adolescence/Early Adulthood and Risk for Premenopausal Breast Cancer
Although adolescence is a highly susceptible time for mammary carcinogenesis, few prospective studies have examined the role of adolescent diet and breast cancer risk. Now, a study investigating the association of an adolescent and early adulthood dietary pattern that promotes chronic inflammation...
ASCO Quality Care 2017: Mental Health Conditions Contribute to Care-Related Costs, Hospital Visits in Breast and Prostate Cancers
A new analysis of data from the U.S. Military Health System found that mood and adjustment disorders such as anxiety and depression were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with breast and prostate...
ASCO Quality Care 2017: Study Examines Cancer Center Websites’ Information on Breast Cancer Treatment, Outcomes
As an increasing number of patients look to the internet for cancer information, researchers from the University of Alabama found that the websites of many National Cancer Institute (NCI)-designated cancer centers lack sufficient information to help patients with breast cancer understand all their...
ASCO Quality Care 2017: In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors
An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in...
Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy
Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations
Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, which will be the future of lung cancer immunotherapy.
Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.
Marie-Andrée Forget, PhD, on Metastatic Melanoma: Update From MD Anderson
Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma. (Abstract 138)
Limo Chen, PhD, on Lung Cancer and CD38: Resistance to Immunotherapy
Limo Chen, PhD, of The University of Texas MD Anderson Cancer Center, discusses co-inhibition of CD38 and PD-L1, which leads to improved antitumor immune response, reducing tumor growth and metastasis. (Abstract 79)
Patient-Reported Outcomes for Assessing Symptom Burden in Patients Receiving Oral Anticancer Therapy
In a study reported in the Journal of Oncology Practice, Mackler et al found that use of a validated symptom assessment tool for patient-reported outcomes was feasible in evaluating symptom burden in outpatients receiving oral anticancer treatment in the clinical setting. Study Details The study...
